Yi Zhu,Tamara Tchkonia,Tamar Pirtskhalava,Adam C Gower,Husheng Ding,Nino Giorgadze,Allyson K Palmer,Yuji Ikeno,Gene B Hubbard,Marc Lenburg,Steven P O’Hara,Nicholas F LaRusso,Jordan D Miller,Carolyn M Roos,Grace C Verzosa,Nathan K LeBrasseur,Jonathan D Wren,Joshua N Farr,Sundeep Khosla,Michael B Stout,Sara J McGowan,Heike Fuhrmann-Stroissnigg,Aditi U Gurkar,Jing Zhao,Debora Colangelo,Akaitz Dorronsoro,Yuan Yuan Ling,Amira S Barghouthy,Diana C Navarro,Tokio Sano,Paul D Robbins,Laura J Niedernhofer,James L Kirkland,Adam C. Gower,Allyson K. Palmer,Gene B. Hubbard,Steven P. O'Hara,Nicholas F. LaRusso,Jordan D. Miller,Carolyn M. Roos,Grace C. Verzosa,Nathan K. LeBrasseur,Jonathan D. Wren,Joshua N. Farr,Michael B. Stout,Sara J. McGowan,Heike Fuhrmann‐Stroissnigg,Aditi U. Gurkar,Amira S. Barghouthy,Diana C. Navarro,Paul D. Robbins,Laura J. Niedernhofer,James L. Kirkland

Abstract:The healthspan of mice is enhanced by killing senescent cells using a transgenic suicide gene. Achieving the same using small molecules would have a tremendous impact on quality of life and the burden of age-related chronic diseases. Here, we describe the rationale for identification and validation of a new class of drugs termed senolytics, which selectively kill senescent cells. By transcript analysis, we discovered increased expression of pro-survival networks in senescent cells, consistent with their established resistance to apoptosis. Using siRNA to silence expression of key nodes of this network, including ephrins (EFNB1 or 3), PI3Kδ, p21, BCL-xL, or plasminogen-activated inhibitor-2, killed senescent cells, but not proliferating or quiescent, differentiated cells. Drugs targeting these same factors selectively killed senescent cells. Dasatinib eliminated senescent human fat cell progenitors, while quercetin was more effective against senescent human endothelial cells and mouse BM-MSCs. The combination of dasatinib and quercetin was effective in eliminating senescent MEFs. In vivo, this combination reduced senescent cell burden in chronologically aged, radiation-exposed, and progeroid Ercc1(-/Δ) mice. In old mice, cardiac function and carotid vascular reactivity were improved 5 days after a single dose. Following irradiation of one limb in mice, a single dose led to improved exercise capacity for at least 7 months following drug treatment. Periodic drug administration extended healthspan in Ercc1(-/∆) mice, delaying age-related symptoms and pathology, osteoporosis, and loss of intervertebral disk proteoglycans. These results demonstrate the feasibility of selectively ablating senescent cells and the efficacy of senolytics for alleviating symptoms of frailty and extending healthspan.

Inhibitor PF-04691502 works as a senolytic to regulate cellular senescence

Targeted clearance of senescent cells using an antibody-drug conjugate against a specific membrane marker

Discovery of piperlongumine as a potential novel lead for the development of senolytic agents

Combined inhibition of class 1-PI3K-alpha and delta isoforms causes senolysis by inducing p21 WAF1/CIP1 proteasomal degradation in senescent cells

Development of novel flavonoid senolytics through phenotypic drug screening and drug design

Peptide inhibitors targeting FOXO4-p53 interactions and inducing senescent cancer cell-specific apoptosis

Repurposing the plant-derived compound apigenin for senomorphic effect in antiaging pipelines

Elimination of senescent cells by β-galactosidase-targeted prodrug attenuates inflammation and restores physical function in aged mice

Senolytics improve physical function and increase lifespan in old age

An in vivo screening platform identifies senolytic compounds that target p16INK4a+ fibroblasts in lung fibrosis

Senolytic activity of piperlongumine analogues: Synthesis and biological evaluation

Senolytic Therapy Enabled by Senescent Cell‐Sensitive Biomimetic Melanin Nano‐senolytics

Cycloastragenol: A Novel Senolytic Agent That Induces Senescent Cell Apoptosis and Restores Physical Function in TBI-Aged Mice

Design and optimization of piperlongumine analogs as potent senolytics

Identification of gingerenone A as a novel senolytic compound

The Achilles’ heel of senescent cells: from transcriptome to senolytic drugs

Procyanidin C1 is a natural agent with senolytic activity against aging and age-related diseases

Identification of lipid senolytics targeting senescent cells through ferroptosis induction

Senescent Cell Depletion Through Targeting BCL-Family Proteins and Mitochondria

Pan-mTOR inhibitors sensitize the senolytic activity of navitoclax via mTORC2 inhibition-mediated apoptotic signaling

Identification of HSP90 inhibitors as a novel class of senolytics